We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| BeiGene Ltd | NASDAQ:BGNE | NASDAQ | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.88 | 2.42% | 164.44 | 160.00 | 163.47 | 168.46 | 161.38 | 165.49 | 220,950 | 00:12:12 |
From May 2019 to May 2024
By Stephen Nakrosis
The U.S. Food and Drug Administration said Thursday it had granted accelerated approval to BeiGene Ltd.'s (BGNE) Brukinsa, or zanubrutinib, for the treatment of certain adult patients with lymphoma.
The FDA said the approval was granted "for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy."
According to the FDA, clinical trials showed 84% of patients saw tumor shrinkage with BeiGene's therapy.
BeiGene's application was given a breakthrough therapy designation, the FDA said, which "expedites the development and review of drugs that are intended to treat a serious condition."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
November 14, 2019 16:22 ET (21:22 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year BeiGene Chart |
1 Month BeiGene Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
